3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
26
Phase 1
23
Phase 1/2
8
Phase 3
6
Phase EARLY_PHASE1
2
Phase 4
2
Phase 2/3
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Breast
2
Head & Neck
1
Genitourinary
1
Conditions
Ovarian Neoplasms
2
Breast Neoplasms
2
Thyroid Neoplasms
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
BRCA or HRR+ Mutated Ovarian Cancer Patients
1
Interventions
Letrozole
20
Docetaxel
16
Cyclophosphamide
13
Zoledronic Acid
12
exemestane
11
Trastuzumab
11
Anastrozole
11
Paclitaxel
10
Tamoxifen
9
Capecitabine
9
Fulvestrant
8
Epirubicin
8
pegfilgrastim
7
pertuzumab
6
liposomal doxorubicin
6
abemaciclib
6
Saline Solution
6
palbociclib
5
Sodium Chloride
5
Dexmedetomidine
5
Carboplatin
5
Bupivacaine
5
Bevacizumab
5
ribociclib
4
pegylated granulocyte colony-stimulating factor
4
eribulin
4
Tranexamic Acid
4
Standard of Care
4
Pamidronate
4
Filgrastim
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
Breast Neoplasms
×
olaparib
×
Clear all
NCT04330040
2025-03-10
SOLI
AstraZeneca
Phase 4
Completed
202 enrolled
15 charts
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled